Cubist Systematic Strategies LLC Invests $494,000 in Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Cubist Systematic Strategies LLC purchased a new position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 568,975 shares of the company’s stock, valued at approximately $494,000. Cubist Systematic Strategies LLC owned about 0.46% of Karyopharm Therapeutics as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. AQR Capital Management LLC grew its stake in Karyopharm Therapeutics by 494.5% in the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock valued at $649,000 after buying an additional 622,194 shares in the last quarter. Acadian Asset Management LLC purchased a new position in Karyopharm Therapeutics in the 2nd quarter valued at approximately $167,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Karyopharm Therapeutics in the 2nd quarter valued at approximately $143,000. Point72 DIFC Ltd purchased a new position in Karyopharm Therapeutics in the 2nd quarter valued at approximately $31,000. Finally, Ikarian Capital LLC grew its stake in Karyopharm Therapeutics by 2.3% in the 1st quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock valued at $618,000 after buying an additional 9,355 shares in the last quarter. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Stock Performance

NASDAQ KPTI opened at $0.86 on Friday. Karyopharm Therapeutics Inc. has a 52-week low of $0.62 and a 52-week high of $1.95. The company has a market capitalization of $107.32 million, a P/E ratio of -0.68 and a beta of 0.20. The company has a fifty day moving average of $0.79 and a 200-day moving average of $0.97.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.09. The company had revenue of $42.79 million for the quarter, compared to the consensus estimate of $36.07 million. As a group, analysts forecast that Karyopharm Therapeutics Inc. will post -0.93 EPS for the current fiscal year.

Analyst Ratings Changes

KPTI has been the subject of a number of recent research reports. StockNews.com upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. Robert W. Baird cut their price target on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $4.80.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).